Rheumatology SAMPLE (Specimen And Matched Phenotype Linked Evaluation) Registry and Biorepository
In this research proposal, we will develop a clinical registry containing information related to the patient’s ethnicity, race, gender, age, medications, specific disease or state of health and biorepository (tissue bank collection of blood samples, urine, and feces) of patients with autoimmune and rheumatic diseases, including but not limited to rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriatic arthritis, Sjogren’s syndrome, gout, anti-phospholipid syndrome (aPLS), Behςet’s Disease and other forms of inflammatory arthritis. In addition, we will develop a biorepository for healthy individuals without autoimmune rheumatic diseases, as well as for healthy individuals who may be related to a patient with an autoimmune and rheumatic disease. The scientific objective is to understand what factors contribute to the risk of getting an autoimmune and/or rheumatic disease, what factors make the disease worse, what factors relate to whether a therapy helps improve disease, and what factors lead to health problems other than the specific disease. For this purpose, electronic medical records will be reviewed and subjects will complete disease-targeted questionnaires (listed in study design) that are part of the standard of care for management of the specific rheumatic disease. A biorepository (tissue bank) will be developed for the storage of genetic material (DNA), blood cell RNA, plasma, serum, feces, urine, and lymphoblastoid cell lines (LCLs) from patients with these autoimmune and/or rheumatic diseases and healthy individuals. These materials will be used in basic science investigations of the pathogenesis of disease, and will also be used in translational research projects that will correlate the clinical characteristics and responses to treatment at NYU. Specifically, examples of the types of studies to be done include but are not limited to: 1) targeted genetic assays for single nucleotide polymorphisms (SNPs) of candidate genes (e.g. TNF, IL6, IL23), as well as genome-wide platforms for empiric-based analyses using genome wide association study (GWAS) approaches; 2) transcript-based assays of candidate gene expression (e.g. interferon-related genes) as well as empiric-based broader approaches (full transcriptome); 3) serum and plasma assays for specific autoantibodies (e.g. citrullinated peptide antibodies), secreted proteins (e.g. cytokines) that can be measured using proteomic assays (e.g. ELISA and other techniques); urine for markers of tissue/organ catabolism/damage; 4) stool samples for 16S DNA bacterial DNA sequence and whole-genome shotgun-sequence determinations for characterization of the microbiome (3) (4-6) (7) (8), and 5) discovery of Quantitative Trait Loci (eQTLs) of LCLs. Repeat sampling and clinical data collection will be needed. These studies may or may not affect treatment or determine prognosis for an individual subject. However, a potential benefit of this research includes the possibility of finding a marker that predicts a response to therapy representing information which may be useful to future patients.
Rheumatology Services | NYU Langone Health
Doctors at NYU Langone Orthopedic Center specialize in arthritis and diseases related to joints, soft tissue, and autoimmunity.
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) A COG Groupwide Phase 3 Study
This is a phase III study using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Patients will be divided into seven groups. Six groups of patients will receive chemotherapy medicine, and one group of patients will have a surgery called Nephrectomy done. The six groups will get the chemotherapy medicines as below:Group 1-(vincristine, dactinomycin), Group 2-( vincristine, dactinomycin, doxorubicin), Group 3- (vincristine, dactinomycin, irinotecan), Group 4- (vincristine, dactinomycin, doxorubicin, cyclophosphamide and etoposide), Group 5- (vincristine, dactinomycin, doxorubicin, cyclophosphamide, etoposide and irinotecan), and Group 6- (vincristine, doxorubicin, cyclophosphamide, etoposide, carboplatin and irinotecan). All patients will have blood samples taken to see how they are doing. All patients will have special scans taken to see how the study treatment is changing their cancer. The study team will closely monitor all patients for any side effects and safety concerns throughout the study.
Risk Evaluation, Assessment & Care for Hereditary Cancer Surveillance Program | NYU Langone Health
NYU Langone’s REACH Program offers cancer surveillance and risk management for those with genetic cancer risks or a family history of cancer.
Risk factors for sudden unexplained death in epilepsy (SUDEP)
The registry is a database created to document SUDEP (sudden unexplained death in epilepsy patients) cases. Our goals are to increase knowledge and awareness about epilepsy related mortality. We are interested in obtaining clinical records and DNA and/or brain tissue - on suspected SUDEP cases.
Risks & Benefits of Weight Loss Surgery | NYU Langone Health
At NYU Langone’s Weight Management Program, we educate patients on the most common risks and benefits of bariatric surgery for weight loss.
Robert I. Grossman, MD | NYU Langone Health
Dr. Robert I. Grossman is executive vice president to the Board of Trustees of NYU Langone Health.
Robotic-Assisted Surgery for Ureteral Stricture | NYU Langone Health
NYU Langone urologic surgeons have pioneered robotic-assisted surgery to correct ureteral stricture.
Robotic Mitral Valve Repair for Mitral Valve Disease | NYU Langone Health
NYU Langone cardiothoracic surgeons use robotic mitral valve repair to repair damaged mitral valves.
Robotic Orthopedic Surgery | NYU Langone Health
NYU Langone orthopedic surgeons specialize in robotic and computer-assisted surgical techniques for hip and knee replacement procedures.